The Future Is Now: EMA Qualification Favors Clinical Trial eSource Solutions Over Outdated Processes
Despite growing evidence to support the use of eSource solutions for clinical trials, industry acceptance has been slow — mostly due to outdated process models. The EMA’s opinion should help to increase the adoption of these electronic data capture technologies industry-wide.
Join this free webinar to learn about the implications behind the EMA’s qualification opinion and the benefits of using eSource solutions in clinical trial conduct.
Webinar Type: Recorded
Ed Seguine, CEO, Clinical Ink
Ed Seguine brings more than 20 years of experience as a clinical technology executive at big pharma and start-up organizations to the Clinical Ink team. Mr. Seguine joined Clinical Ink in late 2009 with the goal of creating a company that would eliminate problems caused by current paper-based processes and technologies.
Prior to joining Clinical Ink, he served as general manager, trial planning at Medidata Solutions, where he managed acquisition integration activities and product positioning prior to the company’s IPO. He also served as CEO of Fast Track Systems, where he oversaw the turnaround process and established early commercial successes for a novel product that became the rationale for acquisition by Medidata Solutions. Prior to Fast Track, Mr. Seguine was a founding manager of the Eli Lilly & Co. venture capital funds, e.Lilly and Lilly Bioventures, focusing on technology and biotech and device companies. Mr. Seguine has also been intimately involved with key industry initiatives, including Clinical Data Interchange Standards Consortium (CDISC) and eClinical Forum. He is a frequent presenter at industry events and publishes regularly. Mr. Seguine earned a Master of Business Administration from Indiana University-Bloomington and a Bachelor’s degree in Finance from Brigham Young University.
Jonathan Andrus, Chief Business Officer, Clinical Ink
Jonathan Andrus has more than two decades of experience developing eClinical solutions that integrate data and technology to help life science companies optimize study execution. As chief business officer at Clinical Ink, he is focused on helping study sponsors and clinical research organizations (CROs) better leverage eSource, eCOA and ePRO data for use throughout their trials. Johnathan has spent his career in leadership positions at eClinical service and technology organizations, supporting industry associations like SCDM, CDISC, DIA and ASQ. Thanks to his vast industry experience, he is also an active thought leader, blogger and presenter. At Clinical Ink, Johnathan also works on building relationships and forging strategic partnerships with sponsors, CROs, regulatory bodies and clinical research professionals across the industry.